Irazu is developing a vaccine platform that utilizes Outer Membrane Vesicles OMVs from engineered bacteria to deliver tumor antigens, stimulating the immune system to target and destroy cancer cells. This technology enables rapid, cost-effective production of customizable vaccines applicable to a wide range of solid tumors, addressing the need for more effective cancer treatment options.
Funding
$2.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatment options often lack the specificity needed to target tumor cells effectively, leading to systemic toxicity and limited efficacy, especially for solid tumors. Traditional vaccine development is slow and expensive, hindering the rapid creation of personalized immunotherapies.
Solution
Irazu is developing a vaccine platform based on Outer Membrane Vesicles (OMVs) derived from engineered bacteria. These OMVs display tumor-associated antigens on their surface, stimulating the patient's immune system to recognize and destroy cancer cells. The platform enables rapid and cost-effective production of customizable vaccines applicable to a broad range of solid tumors. By leveraging the inherent adjuvant properties of OMVs and the ability to easily incorporate different tumor antigens, Irazu aims to create personalized cancer vaccines that are both effective and scalable.
Target Audience
The primary target audience includes patients with solid tumors who are seeking more effective and less toxic treatment options, as well as oncologists and researchers interested in personalized cancer immunotherapies.
Features
- Engineered bacteria produce OMVs displaying tumor-specific antigens.
- Customizable antigen cassettes allow for rapid adaptation to different tumor types.
- OMVs are size-selected to enhance uptake by lymph nodes, promoting a robust immune response.
- Self-adjuvanting properties of OMVs eliminate the need for additional adjuvants.
- Platform enables rapid design and low-cost production of vaccines.